Friday, January 15, 2021 1:32:11 PM
John Nelson - latest post mentions Vascepa - great read
Director at California Cardiovascular Institute
https://www.linkedin.com/pulse/remnant-cholesterolnot-ldl-cholesterolis-associated-john/?trackingId=M8oPD7DAhdWT6L2xtCPxPw%3D%3D
This is the title of the study just published in JACC vol 76(No.23) :2712-24) authored by Dr.Olga Castner et al.There are several ,very important comments made in this manuscript that I fully endorse. I have recommended treatment of elevated remnant lipoprotein cholesterol(remnant-C) in high risk patients for many years.
Study Design: "The PREDIMED study was a multi-center,randomized clinical trial that tested the efficacy of MedDiets enriched with extra-virgin olive oil or mixed nuts against a control diet diet for the primary prevention of CVD in older patients at high CV risk'
Remnant lipoprotein cholesterol (Remnant-C) was simply measured as Total cholesterol minus LDL-c minus HDL-c.(As us lipidologists know this converts to Triglycerides/5)
In multivariable -adjusted analysis,triglycerides(HR):1.04;95%CI:1.02 to 1.06,per 10mg/dl(0.11mmol/l);p<0.001,non-HDL-C(HR):1.05;95% CI:1.01 to 1.10,per 10mg/dl(0.26mmol/l);p=0.026) and remnant-C(HR:1.21;95% CI: 1.10 to 1.33 per 10mg/dl(0.26mmol/l);p<0.001), but not LDL-C or HDL-C were associated with MACEs.
"Remnant-c was the major cholesterol fraction contributor to MACEs in our cohort of participants at high cardiovascular risk but who had no previous CVD;these subjects had moderately elevated triglyceride concentrations and a high frequency of statin treatment"
"Participants with Remnant-c levels >/= 30mg/dl (75th percentile of the cohort)had a higher risk of MACEs,regardless of whether LDL-c was at optimal levels(</=100mg/dl;2.59mmole/l)."
"From the present data,it could be inferred that treatment of residual risk,measured as triglycerides or remnant-C,was probably more beneficial than further reducing LDL-c in high-risk subjects in primary prevention not eligible for statin treatment or already treated with moderate- or high dose statins"
Take a look at Figure 4 and the LDL-c and remnant-C Kaplan-Meier curves.....Amazing!!!
Mt Hat is off to Dr.Olga Castaner and colleagues for a such a wonderful and extremely clinically relevant paper
I would like to add that the FDA approved ,prescription icosapent ethyl plays a key role in reducing CV events in patients with Triglycerides >/=150mg/dl with CVD or DM and 2 or more additional risk factors for CVD.
For those who want to read more about "The Role of Remnant Lipoproteins in Atherogenesis" I refer you to the paper authored by myself and Paul N. Hopkins,MD,MSPH published in the National Lipid Associations Lipid Spin Volume 11(2) Spring Issue 2013,pages12-15,38-39.
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM